secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0000950170-24-067662
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan reports Phase 2b zipalertinib data: 39% ORR in post-amivantamab NSCLC patients
--------------------------------------------------------------------------------

- ORR of 39% (confirmed) and DCR of 94% in 18 evaluable patients; median DOR and PFS not yet reached.
- No grade 4 or 5 treatment-related adverse events; safety profile manageable and consistent with prior data.
- Data cut-off Jan 12, 2024; patients received median 3 prior therapies including chemo, anti-PD1/L1, and EGFR TKI.
- Enrollment in pivotal REZILIENT1 trial (Modules B2 and C) on track to complete by end of 2024.
- Partnership with Taiho: upfront $275M plus up to $130M in milestones; 50/50 US profit share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024067662/0000950170-24-067662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024067662/cgem-20240601.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-067662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer